Hepatitis C and Orphan Diseases Driving Big Biotech Potential: Geoff Meacham

J.P. Morgan Important Disclosures:

Regeneron Pharmaceuticals (REGN)
Important Disclosures:

• Market Maker: JPMS makes a market in the stock of Regeneron Pharmaceuticals.
• Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Regeneron Pharmaceuticals.
• Client/Non-Investment Banking, Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Regeneron Pharmaceuticals.
• Client/Non-Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-securities-related: Regeneron Pharmaceuticals.
• Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Regeneron Pharmaceuticals.

Gilead Sciences (GILD)
Important Disclosures:

• Market Maker: JPMS makes a market in the stock of Gilead Sciences.
• Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for Gilead Sciences within the past 12 months.
• Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Gilead Sciences.
• Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: Gilead Sciences.
• Client/Non-Investment Banking, Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Gilead Sciences.
• Client/Non-Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-securities-related: Gilead Sciences.
• Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation for investment banking Gilead Sciences.
• Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Gilead Sciences.
• Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Gilead Sciences.

Idenix Pharmaceuticals (IDIX)
Important Disclosures:

• Market Maker: JPMS makes a market in the stock of Idenix Pharmaceuticals.
• Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for Idenix Pharmaceuticals within the past 12 months.
• Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Idenix Pharmaceuticals.
• Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: Idenix Pharmaceuticals.
• Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation for investment banking Idenix Pharmaceuticals.
• Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Idenix Pharmaceuticals.

ViroPharma Incorporated (VPHM)
Important Disclosures:

• Market Maker: JPMS makes a market in the stock of ViroPharma Incorporated.
• Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for ViroPharma Incorporated within the past 12 months.
• Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: ViroPharma Incorporated.
• Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: ViroPharma Incorporated.
• Client/Non-Investment Banking, Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: ViroPharma Incorporated.
• Client/Non-Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-securities-related: ViroPharma Incorporated.
• Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation for investment banking ViroPharma Incorporated.
• Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from ViroPharma Incorporated.
• Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from ViroPharma Incorporated.

Alexion Pharmaceuticals (ALXN)
Important Disclosures:

• Market Maker: JPMS makes a market in the stock of Alexion Pharmaceuticals.
• Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for Alexion Pharmaceuticals within the past 12 months.
• Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Alexion Pharmaceuticals.
• Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: Alexion Pharmaceuticals.
• Client/Non-Investment Banking, Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Alexion Pharmaceuticals.
• Client/Non-Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-securities-related: Alexion Pharmaceuticals.
• Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation for investment banking Alexion Pharmaceuticals.
• Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Alexion Pharmaceuticals.
• Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Alexion Pharmaceuticals.

InterMune (ITMN)
Important Disclosures:

• Market Maker: JPMS makes a market in the stock of InterMune.
• Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for InterMune within the past 12 months.
• Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: InterMune.
• Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: InterMune.
• Client/Non-Investment Banking, Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: InterMune.
• Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation for investment banking InterMune.
• Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from InterMune.
• Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from InterMune.

Celgene (CELG)
Important Disclosures:

• Market Maker: JPMS makes a market in the stock of Celgene.
• Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for Celgene within the past 12 months.
• Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Celgene.
• Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: Celgene.
• Client/Non-Investment Banking, Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Celgene.
• Client/Non-Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-securities-related: Celgene.
• Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation for investment banking Celgene.
• Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Celgene.
• Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Celgene.

Amgen Inc. (AMGN)
Important Disclosures:

• Market Maker: JPMS makes a market in the stock of Amgen Inc.
• Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for Amgen Inc within the past 12 months.
• Analyst Position: The following analysts (and/or their associates or household members) own a long position in the shares of Amgen Inc.: Katherine Khor.
• Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Amgen Inc.
• Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: Amgen Inc.
• Client/Non-Investment Banking, Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Amgen Inc.
• Client/Non-Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-securities-related: Amgen Inc.
• Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation for investment banking Amgen Inc.
• Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Amgen Inc.
• Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Amgen Inc.

Biogen Idec (BIIB)
Important Disclosures:

• Market Maker: JPMS makes a market in the stock of Biogen Idec.
• Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Biogen Idec.
• Client/Non-Investment Banking, Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Biogen Idec.
• Client/Non-Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-securities-related: Biogen Idec.
• Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Biogen Idec.

Vertex Pharmaceuticals (VRTX)
Important Disclosures:

• Market Maker: JPMS makes a market in the stock of Vertex Pharmaceuticals.
• Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Vertex Pharmaceuticals.

For any JPM conflicts on any additional companies mentioned, please refer to JPM's website.